A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.